Replimune Group (NASDAQ:REPL) Stock Price Down 10.6%

Replimune Group Inc (NASDAQ:REPL)’s share price traded down 10.6% during mid-day trading on Friday . The stock traded as low as $12.20 and last traded at $12.20, 819,800 shares changed hands during trading. An increase of 1,066% from the average session volume of 70,303 shares. The stock had previously closed at $13.64.

Several research analysts have issued reports on the stock. Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of Replimune Group in a report on Thursday, October 24th. Roth Capital raised their price target on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Zacks Investment Research lowered shares of Replimune Group from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of Replimune Group in a report on Monday, September 30th. Finally, ValuEngine upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Replimune Group currently has an average rating of “Buy” and an average target price of $25.17.

The firm’s fifty day simple moving average is $14.49 and its 200-day simple moving average is $13.44. The company has a debt-to-equity ratio of 0.16, a quick ratio of 9.79 and a current ratio of 9.85. The stock has a market cap of $436.60 million, a P/E ratio of -9.17 and a beta of 3.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). Analysts predict that Replimune Group Inc will post -1.4 earnings per share for the current fiscal year.

In related news, COO Colin Love sold 11,250 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $17.05, for a total value of $191,812.50. Also, CEO Robert Coffin sold 48,500 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $16.92, for a total transaction of $820,620.00. Insiders sold a total of 200,000 shares of company stock worth $3,395,500 over the last three months. 63.18% of the stock is owned by insiders.

Several large investors have recently modified their holdings of REPL. BlackRock Inc. boosted its holdings in shares of Replimune Group by 8.2% in the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after buying an additional 76,540 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Replimune Group by 7.3% during the second quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock valued at $7,866,000 after purchasing an additional 36,547 shares during the last quarter. Emerald Advisers LLC lifted its holdings in Replimune Group by 5.2% during the third quarter. Emerald Advisers LLC now owns 728,890 shares of the company’s stock valued at $10,132,000 after purchasing an additional 35,712 shares during the last quarter. Foresite Capital Management III LLC lifted its holdings in Replimune Group by 4.0% during the second quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock valued at $11,430,000 after purchasing an additional 30,002 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in Replimune Group by 3.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 733,404 shares of the company’s stock valued at $10,194,000 after purchasing an additional 21,634 shares during the last quarter. 60.92% of the stock is currently owned by institutional investors.

About Replimune Group (NASDAQ:REPL)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

See Also: Trading based on a resistance level

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.